ENTA · Enanta Pharmaceuticals Inc
$12.44
-0.17 (-1.35%)
At close · Jul 29
Market Cap
$366.68M
Shares
29.08M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$12.61
Open$12.70
Day$12.44–12.74
52W$6.45–17.15
Avg vol 30d214K
Short int2.4M · 8.4% float · 12.8d
Short vol37%
Last earningsNov 25, 2024
DataJan 2020–Jul 2026
Filing10-Q · May 13
Up next
FQ4-26 quarter ends
~Sep 30, 2026
Est
filed May 13, 2026
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 18.2 · elevated
Equity put/call 0.71
Technical
price trend
50 / 200-day cross
Death cross
Price vs 200-day avg
−5%
below
Price vs 50-day avg
−4%
below
RSI (14)
40
neutral
MACD trend
Negative
52-week position
58%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−13%
trailing
6-month return
−7%
trailing
YTD return
−20%
this year
Relative strength
−15%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
Death cross
50d $13 › 200d $13 — 200d above 50d
Institutional flow
Accumulating
19 of 132 funds reported for Jun 30 · net +1.7K sh shares · +2 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
8.40% of float · ▼ -5.5% MoM · 12.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
132 holders — mid 3-yr range
Squeeze score
68
elevated · 0–100
Fundamentals
Revenue growth
+16%
Y/Y
EPS growth
+30%
Y/Y
Free cash flow
$-32.2M
Balance sheet
$32.3M
net cash
Quant / Vol
risk profile
Volatility
109%
annualized · 1-yr
Max drawdown
−34%
past year
ATR
5.2%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
Death cross
Bearish
Price vs 200-day avg
−5%
Bearish
Price vs 50-day avg
−4%
Neutral
RSI (14)
40
Neutral
MACD trend
Negative
Bearish
52-week position
58%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
Death cross
50d $13 › 200d $13 — 200d above 50d
Institutional flow
Accumulating
19 of 132 funds reported for Jun 30 · net +1.7K sh shares · +2 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
8.40% of float · ▼ -5.5% MoM · 12.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
132 holders — mid 3-yr range
Price context
position in its 52-week range
52-wk low $6
Now $13 · 58%
52-wk high $17
vs 200-day avg -5%
vs 50-day avg -4%
50-day below 200-day death cross
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ENTA
this stock
Enanta Pharmaceuticals Inc
|
$366.68M | -20.0% | +16.5% | — | 8.4% |
|
ONC
BeOne Medicines Ltd.
|
$474.96B | +8.8% | +22179.2% | 966.6 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$124.46B | +8.2% | +46.2% | 29.1 | 2.0% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$72.88B | -9.8% | +20.8% | 17.0 | 3.3% |
|
ARGX
Argenx SE
|
$54.57B | +3.7% | — | — | 2.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ENTA | -6.0% | -13.1% | -7.1% | -13.5% | -20.0% |
| SPY | -1.0% | 0.0% | +7.4% | -0.8% | +8.6% |
| vs SPY | -5.1% | -13.1% | -14.5% | -12.7% | -28.7% |
Key facts
CIK
1177648
CUSIP
29251M106
13F (30d)
38 filings
17 filers
Visit website
Investor relations